Request for Information Cpe Cbrnd Seeking Device Capable Tender

• Country: USA
• Summary: Request for Information Cpe Cbrnd Seeking Device Capable of Delivering Medical Countermeasure Via Inhalation and Intramuscular Routes
• UST Ref No: 138231713
• Deadline: 03 Apr 2026
• Financier: Self Financed
• Purchaser Ownership: Government
• Tender Value: Refer Document
• Notice Type: Tender
• Document Ref. No.: W911SR-26-R-CBRN
• Purchaser's Detail:
  Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.

  Login to see details
• Description:
• The Joint Project Manager (JPM) for CBRN Medical, under the Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND), serves as the Department of War-s (DoW) premier program management office for the development and acquisition of safe, effective, and innovative medical solutions to combat Chemical, Biological, Radiological and Nuclear (CBRN) threats to service members. JPM CBRN Medical leads medical countermeasure (MCM) development for vaccines, diagnostics, and therapeutics, which are critical elements to an integrated-layered defense strategy.
  The focus of this RFI is to survey current industry capabilities in the development, testing, and manufacturing of devices capable of delivering nalmefene via both inhalation (INH)/intranasal (IN) and intramuscular (IM) routes of administration for both prophylactic and therapeutic purposes. This RFI aims to identify innovative solutions and assess the readiness of industry partners to address emerging operational needs effectively. This market research will also explore alternative methods to deliver both prophylactic and therapeutic MCMs in one device. Technologies must meet the following requirements:
  The device intended for IM and IN/INH delivery must be ruggedized and compliant with military (MIL) standards.
  A single device must be designed to meet the requirements for eventual U.S. Food and Drug Administration (FDA) approval as both a therapeutic and prophylactic product and a medical device.
  Responses to this RFI are requested no later than 12:00 PM ET Friday, 3 April 2026
  Please respond to this RFI with the following details of your system's capability:
  White papers, concept briefs, and technical insights that detail the design feasibility, integration paths, operational readiness, and sustainment strategies for any solutions capable of meeting the above criteria. Summaries of studies performed to date would be beneficial. Submissions should be no more t...
• Documents:

 Tender Notice

Documents.zip